A reduced form of nicotinamide riboside defines a new path for NAD


Journal

Molecular metabolism
ISSN: 2212-8778
Titre abrégé: Mol Metab
Pays: Germany
ID NLM: 101605730

Informations de publication

Date de publication:
12 2019
Historique:
received: 05 06 2019
revised: 13 09 2019
accepted: 28 09 2019
entrez: 27 11 2019
pubmed: 27 11 2019
medline: 24 6 2020
Statut: ppublish

Résumé

A decay in intracellular NAD Through a combination of metabolomics and pharmacological approaches, we describe how NRH, a reduced form of NR, serves as a potent NAD NRH acts as a more potent and faster NAD Our data identify a new pathway for NAD

Identifiants

pubmed: 31767171
pii: S2212-8778(19)30916-0
doi: 10.1016/j.molmet.2019.09.013
pmc: PMC6807296
pii:
doi:

Substances chimiques

Pyridinium Compounds 0
nicotinamide-beta-riboside 0I8H2M0L7N
NAD 0U46U6E8UK
Niacinamide 25X51I8RD4
Phosphotransferases (Alcohol Group Acceptor) EC 2.7.1.-
nicotinamide riboside kinase EC 2.7.1.-

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

192-202

Subventions

Organisme : NCCIH NIH HHS
ID : R21 AT009908
Pays : United States

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier GmbH.. All rights reserved.

Références

Cell Regul. 1991 Mar;2(3):203-9
pubmed: 1830494
Cell Metab. 2016 Aug 9;24(2):269-82
pubmed: 27508874
Methods Mol Biol. 2014;1194:421-36
pubmed: 25064118
Am J Clin Nutr. 2018 Aug 1;108(2):343-353
pubmed: 29992272
Sci Rep. 2016 May 27;6:26933
pubmed: 27230286
J Am Soc Nephrol. 2002 Oct;13(10):2600-10
pubmed: 12239251
Biochem Biophys Res Commun. 2003 Mar 28;303(1):364-9
pubmed: 12646212
Nature. 2016 Mar 24;531(7595):528-32
pubmed: 26982719
Cell Metab. 2015 Jul 7;22(1):31-53
pubmed: 26118927
J Biol Chem. 2009 Dec 11;284(50):34861-9
pubmed: 19846558
Nat Med. 2018 Sep;24(9):1351-1359
pubmed: 30127395
Science. 2016 Jun 17;352(6292):1436-43
pubmed: 27127236
Nature. 2018 Nov;563(7731):354-359
pubmed: 30356218
J Biol Chem. 2015 Nov 6;290(45):27124-37
pubmed: 26385918
J Biol Chem. 2011 Jun 17;286(24):21767-78
pubmed: 21504897
Cell Metab. 2016 Dec 13;24(6):795-806
pubmed: 28068222
Toxins (Basel). 2010 Nov;2(11):2490-518
pubmed: 22069563
J Pharm Biomed Anal. 2002 Oct 15;30(3):773-80
pubmed: 12367703
J Am Soc Nephrol. 2017 Aug;28(8):2337-2352
pubmed: 28246130
Biochem Biophys Res Commun. 1963 Apr 2;11:39-43
pubmed: 14019961
J Clin Invest. 2005 Dec;115(12):3634-40
pubmed: 16322797
Eur J Nutr. 2019 Feb 6;:null
pubmed: 30725213
Nature. 2000 Feb 17;403(6771):795-800
pubmed: 10693811
J Biol Chem. 2003 Mar 14;278(11):9100-6
pubmed: 12509415
Nat Med. 2003 Mar;9(3):352-5
pubmed: 12563315
Nat Commun. 2016 Oct 11;7:13103
pubmed: 27725675
Hepatology. 2016 Apr;63(4):1190-204
pubmed: 26404765
Nat Commun. 2016 Oct 10;7:12948
pubmed: 27721479
Cell. 2007 May 4;129(3):473-84
pubmed: 17482543
Trends Biochem Sci. 2007 Jan;32(1):12-9
pubmed: 17161604
Cell Metab. 2012 Jun 6;15(6):838-47
pubmed: 22682224
Nat Commun. 2018 Mar 29;9(1):1286
pubmed: 29599478
J Biol Chem. 2005 Oct 28;280(43):36334-41
pubmed: 16118205
J Biol Chem. 2003 Mar 14;278(11):9869-74
pubmed: 12522134
Cell. 2013 Jul 18;154(2):430-41
pubmed: 23870130
Cell Metab. 2018 May 01;27(5):1067-1080.e5
pubmed: 29685734
Cell. 2004 May 14;117(4):495-502
pubmed: 15137942
Beilstein J Org Chem. 2019 Feb 13;15:401-430
pubmed: 30873226
Cell Metab. 2011 Oct 5;14(4):528-36
pubmed: 21982712
Biomed Res Int. 2014;2014:967826
pubmed: 25165721
J Biol Chem. 2019 Jun 7;294(23):9295-9307
pubmed: 30948509

Auteurs

Judith Giroud-Gerbetant (J)

Nestlé Institute of Health Sciences, Nestlé Research, EPFL Innovation Park, 1015, Lausanne, Switzerland.

Magali Joffraud (M)

Nestlé Institute of Health Sciences, Nestlé Research, EPFL Innovation Park, 1015, Lausanne, Switzerland.

Maria Pilar Giner (MP)

Nestlé Institute of Health Sciences, Nestlé Research, EPFL Innovation Park, 1015, Lausanne, Switzerland.

Angelique Cercillieux (A)

Nestlé Institute of Health Sciences, Nestlé Research, EPFL Innovation Park, 1015, Lausanne, Switzerland; School of Life Sciences, EPFL, Lausanne, 1015, Switzerland.

Simona Bartova (S)

Nestlé Institute of Health Sciences, Nestlé Research, EPFL Innovation Park, 1015, Lausanne, Switzerland.

Mikhail V Makarov (MV)

Mitchell Cancer Institute, University of South Alabama, 1660 Springhill Avenue, Mobile, 36604, Alabama, USA.

Rubén Zapata-Pérez (R)

Laboratory Genetic Metabolic Diseases, Amsterdam Gastroenterology and Metabolism, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands.

José L Sánchez-García (JL)

Nestlé Institute of Health Sciences, Nestlé Research, EPFL Innovation Park, 1015, Lausanne, Switzerland.

Riekelt H Houtkooper (RH)

Laboratory Genetic Metabolic Diseases, Amsterdam Gastroenterology and Metabolism, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands.

Marie E Migaud (ME)

Mitchell Cancer Institute, University of South Alabama, 1660 Springhill Avenue, Mobile, 36604, Alabama, USA.

Sofia Moco (S)

Nestlé Institute of Health Sciences, Nestlé Research, EPFL Innovation Park, 1015, Lausanne, Switzerland.

Carles Canto (C)

Nestlé Institute of Health Sciences, Nestlé Research, EPFL Innovation Park, 1015, Lausanne, Switzerland; School of Life Sciences, EPFL, Lausanne, 1015, Switzerland. Electronic address: carlos.cantoalvarez@rd.nestle.com.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH